INTRODUCTION TO THE KEYNOTE SPEAKER

Date
May 18, 2024

Presenter


Tracks

Related Products

Thumbnail for NOVEL EPIGENETIC THERAPY FOR HYPERTHERMAL INTRAPERITONEAL CHEMOTHERAPY ENABLES GENE REMODELING OF THE TUMOR MICROENVIRONMENT
NOVEL EPIGENETIC THERAPY FOR HYPERTHERMAL INTRAPERITONEAL CHEMOTHERAPY ENABLES GENE REMODELING OF THE TUMOR MICROENVIRONMENT
INTRODUCTION: Due to its rarity, anal adenocarcinoma (AA) does not have a standardized staging system. The tumor (T) stage of an adenocarcinoma arising from the anal canal could be based on depth of invasion, as for rectal adenocarcinoma, or on size, as in anal squamous cell carcinoma…
Thumbnail for LUNCH AND TRAINEE JEOPARDY!
LUNCH AND TRAINEE JEOPARDY!
LUNCH AND TRAINEE JEOPARDY! 12:00 PM - 1:00 PM LEADERSHIP FORUM, NETWORKING SESSION AND ROUNDTABLES 4:00 PM - 5:30 PM KEYNOTE ADDRESS: FUTURE SCENARIO PLANNING TO PREDICT THE FUTURE OF SURGERY 4:00 PM - 4:30 PM
Thumbnail for Residents & Fellows Research Conference
Residents & Fellows Research Conference
RISK FACTORS FOR REGROWTH AFTER NONOPERATIVE MANAGEMENT FOR RECTAL CANCER
Thumbnail for DNA-HYPOMETHYLATING AGENT DECITABINE COMBINED WITH CAPTEM CHEMOTHERAPY INDUCES REACTIVATION OF TUMOR SUPPRESSOR GENES VIA DOWNREGULATION OF DNMT1 EXPRESSION IN STC-1 NEUROENDOCRINE TUMOR CELLS
DNA-HYPOMETHYLATING AGENT DECITABINE COMBINED WITH CAPTEM CHEMOTHERAPY INDUCES REACTIVATION OF TUMOR SUPPRESSOR GENES VIA DOWNREGULATION OF DNMT1 EXPRESSION IN STC-1 NEUROENDOCRINE TUMOR CELLS
INTRODUCTION: Pancreatic neuroendocrine tumors (PNETs) are a slow-growing, heterogeneous group of neoplasms arising from endocrine tissues of the pancreas. PNETs exhibit a low overall mutational burden, but the genes most commonly mutated are involved in epigenetic regulation…